BRIEF—Can ICER fix what's broken?

The controversial USA-based Institute for Clinical and Economic Review (ICER) is examining its value framework, the rules and assumptions it uses to analyze new drugs’ cost effectiveness. How, the ICER asked, can we improve our approach in 2020 and beyond?

The Institute for Patient Access (IfPA) responded to the ICER's request for comments, outlining some fundamental shortcomings. Recommendations include:

You can read the full comments  here and a summary here.